Training activity information
Details
Prepare a range of interpretative reports for CNS and sarcoma tumours
Type
Developmental training activity (DTA)
Evidence requirements
Evidence the activity has been undertaken by the trainee.
Reflection on the activity at one or more time points after the event including learning from the activity and/or areas of the trainees practice for development.
An action plan to implement learning and/or to address skills or knowledge gaps identified.
Reflective practice guidance
The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.
Before action
- Consider how this activity contributes to your understanding of the clinical significance of somatic and germline variants in specific cancers.
- What knowledge do you have regarding the common genomic alterations and their clinical significance in CNS and sarcoma tumours?
- Are you familiar with the relevant databases and bioinformatic tools used for variant interpretation in these cancer types?
- What are the key elements required in an interpretative report for CNS and sarcoma, including somatic and potentially germline findings?
- Do you understand the importance of pharmacogenomics in the context of these tumour types?
- Consider potential challenges you might face in interpreting novel or variants of unknown significance (VUS) in CNS and sarcoma.
- Review relevant national guidelines, best practice, and literature for genomic reporting in CNS and sarcoma.
- Consider potential difficulties you might face in assigning clinical significance to certain variants and think about how you might access relevant information or support.
In action
- Pay attention to your actions. How are you structuring the report? Why are you including specific pieces of information? What genomic findings are you prioritising in your interpretation? What decisions are you making about the clinical significance of the identified variants? What aspects of report writing feel intuitive, and what requires more conscious effort (e.g., linking genomic findings to tumour type)?
- How effective are you at integrating different pieces of information (e.g., variant data, tumour type, relevant guidelines) into a coherent interpretation? What challenges are you facing while preparing these reports (e.g., ambiguous variant significance, lack of clear guidelines for specific tumour types)? What can you learn about interpreting and reporting genomic data for CNS and sarcoma as you proceed? How does this activity relate to your understanding of these specific tumour types?
- Are there alternative ways you could be phrasing your interpretations to ensure clarity for the intended audience? Do you need to consult any additional resources or seek clarification on specific findings at this moment? Are you ensuring that your report is within the scope of your current knowledge and understanding?
On action
- What did you notice during the process of preparing interpretative reports for CNS and sarcoma tumours? Summarise the key findings you included in the reports and any difficulties you faced.
- What new knowledge or skills did you gain in interpreting genomic data specific to CNS and sarcoma tumours and translating these into a clinical report? Were there any unexpected findings or challenges in the data or the reporting process? What did you learn from these?
- What areas for improvement in your interpretative reporting skills for CNS and sarcoma have you identified? How can you apply the learning from this activity to future report writing? What actions will you take to further develop your skills in this area, and what support or resources might be helpful?
Beyond action
- Have you revisited your reflections on preparing interpretative reports for CNS and sarcoma tumours? How has your approach to reporting on these less common tumour types evolved?
- How has this experience since impacted your current practice in preparing clinical reports? Have you become more confident in interpreting complex data for a wider range of cancers?
- How has preparing these specific reports contributed to your overall training experience, perhaps improving your ability to research rare conditions or interpret less common genomic alterations?
- How has your report writing skill developed since this DTA, particularly when dealing with unfamiliar tumour types or genomic findings?
Relevant learning outcomes
| # | Outcome |
|---|---|
| # 2 |
Outcome
Analyse, interpret and prepare interpretive reports of clinically relevant findings for patients with central nervous system (CNS), sarcoma tumours, and somatic and germline variants in ovarian and breast cancer. |
| # 8 |
Outcome
Practice with relevant specialties for the diagnosis and treatment of cancer patients, and contribute to multidisciplinary team meetings. |